Atulya Deodhar, MD
Rheumatology · Portland, ORNPI 1558376053
Payments from drug & device makers
Across 562 payments — averaging $5870.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.8M
- UCB SA$434K
- E.r. Squibb & Sons, L.L.C.$195K
- Eli Lilly$194K
- Pfizer$131K
- UCB, Inc.$118K
- plus $398K from 24 others
Across 109 payments — averaging $1896.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$87K
- UCB, Inc.$67K
- Pfizer$39K
- AbbVie$10K
- Novartis Pharma AG$4K
- Amgen$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 104 | $1,829,548 |
| UCB SA | 80 | $433,879 |
| E.r. Squibb & Sons, L.L.C. | 28 | $194,906 |
| Eli Lilly | 51 | $194,170 |
| Pfizer | 41 | $130,966 |
| UCB, Inc. | 71 | $117,907 |
| Novartis Pharma AG | 52 | $96,842 |
| Bristol Myers Squibb | 4 | $59,225 |
| UCB GmbH | 5 | $53,403 |
| Janssen Research & Development, LLC | 12 | $45,194 |
| GSK | 17 | $27,206 |
| Janssen Scientific Affairs, LLC | 21 | $25,013 |
| Johnson & Johnson | 25 | $24,452 |
| AbbVie | 5 | $20,795 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $14,275 |
| Amgen | 11 | $7,633 |
| Janssen Global Services, LLC | 3 | $5,463 |
| UCB Biosciences Inc. | 5 | $4,132 |
| Aurinia Pharma U.S., Inc. | 4 | $3,671 |
| Lilly USA, LLC | 3 | $3,164 |
| Boehringer Ingelheim | 1 | $2,800 |
| Cipla USA Inc. | 1 | $1,500 |
| Merck | 8 | $991 |
| Samsung Bioepis Co., Ltd. | 1 | $800 |
| Gilead | 1 | $650 |
| AstraZeneca | 2 | $135 |
| Radius Health, Inc. | 1 | $125 |
| Sanofi | 1 | $121 |
| Genentech USA, Inc. | 1 | $108 |
| Sobi, Inc | 1 | $13 |
How this compares
$3,299,085 in reported general payments places this provider in the 95th percentile of 79 rheumatology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Portland
- Andre BarkhuizenPortland$2.8M
- James RosenbaumPortland$468K
- Cong Qiu ChuPortland$385K
- Rosario BonafedePortland$148K
- Julianna DesmaraisPortland$48K
- Marcia FriedmanPortland$28K
- Kelly PortnoffPortland$13K
- Neha Rich-GargPortland$11K
- Rashmi ShahPortland$5K
- Caroline McCulleyPortland$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.